NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON WEDNESDAY, MAY 24, 2023 Dear Stockholder: You are cordially invited to our 2023. | April 11, 2023
/PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer,.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Reata Announces the Appointments of Christy J. Oliger and Shamim Ruff to Its Board of Directors
Reata Pharmaceuticals, Inc.April 15, 2021 GMT
PLANO, Texas, April 15, 2021 (GLOBE NEWSWIRE) Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the appointments of Christy J. Oliger and Shamim Ruff to its Board of Directors, effective April 15, 2021.
“We are excited to welcome Ms. Ruff and Ms. Oliger to Reata’s board,” said Warren Huff, Reata’s Chief Executive Officer and President. “They join at a critical point in Reata’s development having just submitted our first New Drug Application for bardoxolone methyl (“bardoxolone”) for the treatment of chronic kidney disease caused by Alport syndrome. Both Ms. Ruff and Ms. Oliger bring a wealth of experience that will be invaluable